" class="no-js "lang="en-US"> B dot Medical to Install Proton Therapy System at Hospital in Tokyo
Tuesday, May 28, 2024

B dot Medical to Install Its First Practical Ultra-compact Proton Therapy System at Hospital in Tokyo

B dot Medical has signed a memorandum of understanding with Edogawa Hospital in Japan for the installation of the company’s first practical ultra-compact proton therapy system, which means the first proton therapy facility to be established in Tokyo.

Conventional proton therapy systems are very large and require a large space for installation. As a result, the installation of proton therapy in urban areas where land is scarce has been slow, and proton therapy has reached only a small percentage of patients. To overcome this situation, B dot Medical is working to commercialize an ultra-compact proton therapy system. This system is overwhelmingly more compact than conventional ones and can be installed in hospitals where it has been difficult to do it due to the size and cost of the system in the past.

Dr. Shojiro Kato, Director of Edogawa Hospital, commented: “We are very pleased that once our hospital is able to offer proton therapy, we will be able to treat patients who have not previously been able to receive proton therapy in Tokyo. We will continue to provide medical care in pursuit of the best possible outcome for all patients.”

Takuji Furukawa, Chief Executive Officer of B dot Medical, added: “Three and a half years have passed since we started developing an ultra-compact proton therapy system to bring more advanced cancer treatment to as many patients as possible, and we are finally one step closer to realizing our dream. We hope that the installation of this system will expand the treatment options for many cancer patients. We will do our utmost to obtain approval for the system, install it, start treatment, and provide support afterward.”

B dot Medical will continue its efforts to obtain PMDA (Pharmaceuticals and Medical Devices Agency) approval in Japan, aiming for a society in which cancer patients around the world can choose proton therapy.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more